Lovenox and Granisetron hydrochloride drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Lovenox (enoxaparin sodium) and Granisetron hydrochloride (granisetron hydrochloride). Common drug interactions include abdominal pain among females and malignant neoplasm progression among males.

The phase IV clinical study analyzes what interactions people have when they take Lovenox and Granisetron hydrochloride. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Lovenox?

Lovenox has active ingredients of enoxaparin sodium. It is often used in deep venous thrombosis. eHealthMe is studying from 48,149 Lovenox users. Check the latest studies of Lovenox.

What is Granisetron hydrochloride?

Granisetron hydrochloride has active ingredients of granisetron hydrochloride. eHealthMe is studying from 2,332 Granisetron hydrochloride users. Check the latest studies of Granisetron hydrochloride.



On Jul, 07, 2026

12 people who take Lovenox and Granisetron hydrochloride together, and have interactions are studied.

Lovenox and Granisetron hydrochloride drug interactions.

What are the common drug interactions of Lovenox and Granisetron Hydrochloride, by gender? *:

female:

  1. Abdominal pain
  2. Anaemia (lack of blood)
  3. Escherichia urinary tract infection (urinary tract infection by escherichia coli)
  4. Leukopenia (less number of white blood cells in blood)
  5. Neutropenia (an abnormally low number of neutrophils)
  6. Proteinuria (presence of protein in the urine)
  7. Thrombocytopenia (decrease of platelets in blood)
  8. Thrombocytosis
  9. Urinary tract infection bacterial
  10. Vomiting

male:

  1. Malignant neoplasm progression (cancer tumour came back)
  2. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  3. Productive cough
  4. Rash erythematous (redness of the skin)
  5. Vertigo
  6. Febrile neutropenia (fever with reduced white blood cells)
  7. Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
  8. Back pain
  9. Benign prostatic hyperplasia (benign enlargement of the prostate)
  10. Dehydration (dryness resulting from the removal of water)

What are the common drug interactions of Lovenox and Granisetron Hydrochloride, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Back pain
  2. Dehydration (dryness resulting from the removal of water)
  3. Fatigue (feeling of tiredness)
  4. Hypophagia (reduced food intake)
  5. Lactic acidosis (low ph in body tissues)
  6. Productive cough

40-49:

  1. Chronic kidney disease
  2. Dyspepsia (indigestion)
  3. Renal failure (kidney dysfunction)
  4. Renal injury (kidney injury)
  5. Renal tubular necrosis (death of kidney tubules)
  6. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)

50-59:

n/a

60+:

  1. Abdominal pain
  2. Anaemia (lack of blood)
  3. Malignant neoplasm progression (cancer tumour came back)
  4. Acute myeloid leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts)
  5. Febrile neutropenia (fever with reduced white blood cells)
  6. Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue)
  7. Benign prostatic hyperplasia (benign enlargement of the prostate)
  8. Chest pain
  9. Dyspnoea (difficult or laboured respiration)
  10. Erythema (redness of the skin)

What are the existing conditions these people have? *

  1. High Blood Pressure: 5 people, 41.67%
  2. High Blood Cholesterol: 5 people, 41.67%
  3. Nausea (feeling of having an urge to vomit): 4 people, 33.33%
  4. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 4 people, 33.33%
  5. Nausea And Vomiting: 3 people, 25.00%
  6. Urinary Incontinence (inability to control the flow of urine and involuntary urination): 3 people, 25.00%
  7. Asthma: 3 people, 25.00%
  8. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 25.00%
  9. Constipation: 3 people, 25.00%
  10. Ovarian Cancer (cancer of ovary): 3 people, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lovenox and Granisetron hydrochloride?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Lovenox and Granisetron hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Lovenox:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Granisetron hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Lovenox and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Granisetron hydrochloride and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on enoxaparin sodium and granisetron hydrochloride (the active ingredients of Lovenox and Granisetron hydrochloride, respectively), and Lovenox and Granisetron hydrochloride (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: